Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Urology · Benign Prostatic Hyperplasia

How the Prostate Changes and What Else It Could Be

At a Glance

Benign prostatic hyperplasia usually grows in the part of the prostate around the urethra and can block urine flow, but similar symptoms may come from the bladder, nerves, medicines, infections, or stones. Urine-flow and bladder tests help identify the cause.

While an enlarged prostate may seem like a simple mechanical blockage, it is actually the result of complex biological processes involving hormones, cellular changes, and your overall metabolic health. Understanding how a prostatic adenoma develops can help you and your doctor determine whether your symptoms are truly caused by your prostate or by something else entirely.

The Anatomy of Growth: The Transition Zone

The prostate is divided into different regions, but Benign Prostatic Hyperplasia (BPH) primarily develops in the transition zone—the small area of the prostate that directly wraps around the urethra (the tube that carries urine) [1][2].

As you age, cells in this zone begin to multiply. This involves both stromal cells (connective tissue and smooth muscle) and epithelial cells (glandular tissue) [1][3]. As this benign overgrowth happens, it can create two types of blockage:

  • Static Obstruction: The physical mass of the enlarged tissue pushes against the urethra, narrowing the path for urine [4].
  • Dynamic Obstruction: The smooth muscle within the prostate tissue has its own “tone” or tension. If this muscle stays too tense, it further squeezes the urethra [4][5].

The Role of Hormones and Inflammation

Scientists believe BPH is multifactorial, meaning many things contribute to its development. A key player is a hormone called dihydrotestosterone (DHT). Intraprostatic DHT contributes to the growth of prostate cells [3][6].

Recent research has also identified associations with chronic inflammation. Persistent inflammation in the prostate tissue may contribute to tissue remodeling and fibrosis (scarring) [7][8].

The Metabolic Connection

Your prostate health is also linked to your overall health. Observational research shows an association between metabolic syndrome—a group of conditions including obesity, high blood pressure, and insulin resistance—and BPH [9]. While managing your weight, insulin, and blood pressure is critical for your overall health, treating these metabolic factors has not been proven to reverse BPH directly [9][10].

Mimics: When It’s Not the Prostate

It is a common mistake to assume that any urinary trouble in a man over 50 is caused by BPH. Lower Urinary Tract Symptoms (LUTS) can be caused by many other conditions that “mimic” the feel of an enlarged prostate. It is important to review your medical history, including any prior pelvic or spine surgeries, diabetes, or neurological diseases:

  • Overactive Bladder (OAB): Sometimes the bladder muscle (the detrusor) becomes “twitchy” or overactive, causing urgency and frequency even if the prostate is small [11].
  • Bladder Underactivity: If the bladder muscle is weak, it cannot squeeze hard enough to empty, which can result in poor flow or residual urine even without a blockage [11][12].
  • Neurological Issues: Conditions like Parkinson’s, multiple sclerosis, or poorly controlled diabetes can damage the nerves that control the bladder [11].
  • Medication Side Effects: Common over-the-counter drugs like decongestants (e.g., pseudoephedrine), antihistamines, and some prescription medications (like diuretics or antidepressants) can interfere with bladder or prostate muscles. Do not stop taking prescribed medications without consulting your doctor, but be sure to mention them during your visit [13].
  • Infections and Stones: Urinary tract infections (UTIs) or stones in the bladder can cause pain, frequency, and blood in the urine, overlapping with BPH symptoms [13][14].

Because of these “look-alikes,” tests like uroflowmetry and post-void residual scans are used to show poor flow or incomplete emptying [13][15]. However, to definitively distinguish between a blocked prostate and a weak bladder, specialized pressure-flow urodynamics are sometimes needed.

Common questions in this guide

What is a prostatic adenoma, and where does it grow?
A prostatic adenoma is the benign tissue growth commonly called BPH. It usually develops in the transition zone, the part of the prostate surrounding the urethra. Growth of the tissue and tension in prostate smooth muscle can narrow the urine passage.
What do static and dynamic obstruction mean in BPH?
Static obstruction is narrowing from the physical bulk of enlarged prostate tissue. Dynamic obstruction occurs when smooth muscle in the prostate stays tense and squeezes the urethra. Either or both can reduce urine flow.
Can urinary symptoms be caused by something other than an enlarged prostate?
Yes. An overactive bladder, a weak bladder muscle, nerve disorders, medication effects, urinary infections, and bladder stones can all cause lower urinary tract symptoms, even when the prostate is small. A clinician may need tests to identify the main cause.
Can metabolic syndrome or inflammation affect BPH?
Research has found an association between metabolic syndrome, including obesity, high blood pressure, and insulin resistance, and BPH. Ongoing inflammation may also contribute to changes in prostate tissue. Improving metabolic health is important, but it has not been proven to reverse BPH.
Which tests can show whether the prostate or bladder is causing poor urine flow?
Uroflowmetry measures the speed and pattern of urine flow, and a post-void residual scan checks how much urine remains after urination. If these tests do not show whether the prostate is blocking urine or the bladder is weak, a pressure-flow urodynamics study may help.
Can cold medicines or other medications worsen urinary symptoms?
Yes. Decongestants such as pseudoephedrine, antihistamines, diuretics, and some antidepressants can affect bladder or prostate muscle and worsen urinary symptoms. Do not stop a prescribed medicine on your own; tell your clinician about all prescription and over-the-counter drugs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the physical location of my prostate growth in the transition zone, and is it causing a 'static' or 'dynamic' obstruction?
  2. 2.Given my history of metabolic issues like high blood pressure or insulin resistance, might these be associated with my prostate symptoms?
  3. 3.How can we evaluate whether my symptoms might be caused by an overactive bladder or a weak bladder muscle (detrusor underactivity) rather than just my prostate?
  4. 4.Are any of my current medications, like decongestants or diuretics, possibly making my urinary symptoms worse?
  5. 5.Based on my uroflowmetry and residual volume, do you recommend a pressure-flow study to distinguish if the obstruction is coming from the prostate?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications.

    Dias US, de Moura MRL, Viana PCC, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2021; (41(5)):1509-1530 doi:10.1148/rg.2021200144.

    PMID: 34415807
  2. 2

    Management of Benign Prostatic Hyperplasia in Older Adults.

    Woodard TJ, Manigault KR, McBurrows NN, et al.

    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2016; (31(8)):412-24 doi:10.4140/TCP.n.2016.412.

    PMID: 27535076
  3. 3

    Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.

    Hata J, Harigane Y, Matsuoka K, et al.

    International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411634.

    PMID: 37511400
  4. 4

    Pathophysiological mechanisms of benign prostatic obstruction in men with small prostate volume and the emerging role of ultra-minimally invasive prostatic urethral dilation: a narrative review.

    Shen K, Zhang D, Yu L

    Frontiers in molecular biosciences 2026; (13()):1886121 doi:10.3389/fmolb.2026.1886121.

    PMID: 42620960
  5. 5

    Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

    Minutoli L, Rinaldi M, Marini H, et al.

    International journal of molecular sciences 2016; (17(8)).

    PMID: 27529214
  6. 6

    The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review.

    Vickman RE, Franco OE, Moline DC, et al.

    Asian journal of urology 2020; (7(3)):191-202 doi:10.1016/j.ajur.2019.10.003.

    PMID: 32742923
  7. 7

    Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options.

    Inamura S, Terada N

    International journal of urology : official journal of the Japanese Urological Association 2024; (31(9)):968-974 doi:10.1111/iju.15518.

    PMID: 38934050
  8. 8

    The role of prostate inflammation and fibrosis in lower urinary tract symptoms.

    Bushman WA, Jerde TJ

    American journal of physiology. Renal physiology 2016; (311(4)):F817-F821 doi:10.1152/ajprenal.00602.2015.

    PMID: 27440781
  9. 9

    Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection.

    Fu X, Wang Y, Lu Y, et al.

    Life sciences 2024; (358()):123192 doi:10.1016/j.lfs.2024.123192.

    PMID: 39488266
  10. 10

    Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice.

    Calmasini FB, McCarthy CG, Wenceslau CF, et al.

    Pharmacological reports : PR 2020; (72(1)):179-187 doi:10.1007/s43440-019-00010-3.

    PMID: 32016843
  11. 11

    The Role of the Aging Bladder in Lower Urinary Tract Symptoms: Pathophysiology and Therapeutic Implications in Patients with Benign Prostatic Hyperplasia.

    Papanikolaou D, Diamantopoulos C, Sokolakis I, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(4)) doi:10.3390/medicina62040685.

    PMID: 42075556
  12. 12

    Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms.

    Baboudjian M, Hashim H, Bhatt N, et al.

    European urology 2024; (86(3)):213-220 doi:10.1016/j.eururo.2024.04.004.

    PMID: 38644139
  13. 13

    Pre-therapeutical assessment of lower urinary tract symptoms in adult men: Systematic review and clinical practice guidelines.

    Lebdai S, Doizi S, Kassab D, et al.

    The French journal of urology 2025; (35(3)):102846 doi:10.1016/j.fjurol.2024.102846.

    PMID: 39647566
  14. 14

    Urodynamic risk factors of asymptomatic bacteriuria in men with non-neurogenic lower urinary tract symptoms.

    Ishida S, Matsukawa Y, Yuba T, et al.

    World journal of urology 2022; (40(12)):3035-3041 doi:10.1007/s00345-022-04194-x.

    PMID: 36264427
  15. 15

    EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

    Gratzke C, Bachmann A, Descazeaud A, et al.

    European urology 2015; (67(6)):1099-1109 doi:10.1016/j.eururo.2014.12.038.

    PMID: 25613154

This page explains how BPH can develop and how other conditions can mimic its urinary symptoms for informational purposes only; it does not constitute medical advice. A clinician should interpret your symptoms, medication list, and test results.

Get notified when new evidence is published on prostatic adenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.